What's new in heart failure? May 2025
Mert Tokcan
HOMICAREM (HOMburg Institute for CArdioREnalMetabolic Medicine) and Department of Internal Medicine III, Cardiology, Angiology, Intensive Care Medicine, Universitätsklinikum des Saarlandes, Homburg, Germany
Search for more papers by this authorJulian Hoevelmann
HOMICAREM (HOMburg Institute for CArdioREnalMetabolic Medicine) and Department of Internal Medicine III, Cardiology, Angiology, Intensive Care Medicine, Universitätsklinikum des Saarlandes, Homburg, Germany
Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
Search for more papers by this authorPhilipp Markwirth
HOMICAREM (HOMburg Institute for CArdioREnalMetabolic Medicine) and Department of Internal Medicine III, Cardiology, Angiology, Intensive Care Medicine, Universitätsklinikum des Saarlandes, Homburg, Germany
Search for more papers by this authorCorresponding Author
Bernhard Haring
HOMICAREM (HOMburg Institute for CArdioREnalMetabolic Medicine) and Department of Internal Medicine III, Cardiology, Angiology, Intensive Care Medicine, Universitätsklinikum des Saarlandes, Homburg, Germany
Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA
Corresponding author. Department of Internal Medicine III, Saarland University, Kirrberger Strasse 100, Homburg 66421, Germany. Tel: +49 6841 1651944, Fax: +49 6841 1615032, Email: [email protected]
Search for more papers by this authorMert Tokcan
HOMICAREM (HOMburg Institute for CArdioREnalMetabolic Medicine) and Department of Internal Medicine III, Cardiology, Angiology, Intensive Care Medicine, Universitätsklinikum des Saarlandes, Homburg, Germany
Search for more papers by this authorJulian Hoevelmann
HOMICAREM (HOMburg Institute for CArdioREnalMetabolic Medicine) and Department of Internal Medicine III, Cardiology, Angiology, Intensive Care Medicine, Universitätsklinikum des Saarlandes, Homburg, Germany
Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
Search for more papers by this authorPhilipp Markwirth
HOMICAREM (HOMburg Institute for CArdioREnalMetabolic Medicine) and Department of Internal Medicine III, Cardiology, Angiology, Intensive Care Medicine, Universitätsklinikum des Saarlandes, Homburg, Germany
Search for more papers by this authorCorresponding Author
Bernhard Haring
HOMICAREM (HOMburg Institute for CArdioREnalMetabolic Medicine) and Department of Internal Medicine III, Cardiology, Angiology, Intensive Care Medicine, Universitätsklinikum des Saarlandes, Homburg, Germany
Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA
Corresponding author. Department of Internal Medicine III, Saarland University, Kirrberger Strasse 100, Homburg 66421, Germany. Tel: +49 6841 1651944, Fax: +49 6841 1615032, Email: [email protected]
Search for more papers by this author
References
- 1Tomasoni D, Pagnesi M, Colombo G, Chiarito M, Stolfo D, Baldetti L, et al. Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry. Eur J Heart Fail 2024; 26: 327–337. https://doi.org/10.1002/ejhf.3081
- 2Burnett H, Earley A, Voors AA, Senni M, McMurray JJV, Deschaseaux C, et al. Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction. Circ Heart Fail 2017; 10:e003529. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003529
- 3Zafeiropoulos S, Farmakis IT, Milioglou I, Doundoulakis I, Gorodeski EZ, Konstantinides SV, et al. Pharmacological treatments in heart failure with mildly reduced and preserved ejection fraction: Systematic review and network meta-analysis. JACC Heart Fail 2024; 12: 616–627. https://doi.org/10.1016/j.jchf.2023.07.014
- 4Polhemus DJ, Trivedi RK, Gao J, Li Z, Scarborough AL, Goodchild TT, et al. Renal sympathetic denervation protects the failing heart via inhibition of neprilysin activity in the kidney. J Am Coll Cardiol 2017; 70: 2139–2153. https://doi.org/10.1016/j.jacc.2017.08.056
- 5Yoshimoto T, Naruse M, Tanabe A, Naruse K, Seki T, Imaki T, et al. Potentiation of natriuretic peptide action by the β-adrenergic blocker carvedilol in hypertensive rats: A new antihypertensive mechanism. Endocrinology 1998; 139: 81–88. https://doi.org/10.1210/endo.139.1.5644
- 6Bunsawat K, Ratchford SM, Alpenglow JK, Stehlik J, Smith AS, Richardson RS, et al. Sympathoinhibitory effect of sacubitril-valsartan in heart failure with reduced ejection fraction: A pilot study. Auton Neurosci 2021; 235:102834. https://doi.org/10.1016/j.autneu.2021.102834
- 7Gupta SD, Butt JH, McMurray EGM, Talebi A, Matsumoto S, Rizkala AR, et al.; PARADIGM-HF Investigators and Committees. Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HF. Eur J Heart Fail 2025; 27: 779–787. https://doi.org/10.1002/ejhf.3515
- 8McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993–1004. https://doi.org/10.1056/NEJMoa1409077
- 9Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol 2005; 96: 11G–17G. https://doi.org/10.1016/j.amjcard.2005.07.016
- 10Upshaw JN, Konstam MA, Klaveren D, Noubary F, Huggins GS, Kent DM. Multistate model to predict heart failure hospitalizations and all-cause mortality in outpatients with heart failure with reduced ejection fraction. Circ Heart Fail 2016; 9:e003146. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003146
- 11Kazmi S, Kambhampati C, Rigby AS, Cleland JGF, Kazmi KS, Cuthbert J, et al. Disease progression in chronic heart failure is linear: Insights from multistate modelling. Eur J Heart Fail 2025; 27: 881–888. https://doi.org/10.1002/ejhf.3400
- 12Vazir A, Smith RD, Baldus S. Rescuing patients with post-myocardial infarction mitral regurgitation with transcatheter edge-to-edge repair: A salvation for all mechanisms of mitral regurgitation. Eur J Heart Fail 2025; 27: 922–923. https://doi.org/10.1002/ejhf.3605
- 13Thompson CR, Buller CE, Sleeper LA, Antonelli TA, Webb JG, Jaber WA, et al. Cardiogenic shock due to acute severe mitral regurgitation complicating acute myocardial infarction: A report from the SHOCK Trial Registry. J Am Coll Cardiol 2000; 36: 1104–1109. https://doi.org/10.1016/s0735-1097(00)00846-9
- 14Haberman D, Taramasso M, Czarnecki A, Kerner A, Chrissoheris M, Spargias K, et al. Salvage MitraClip in severe secondary mitral regurgitation complicating acute myocardial infarction: Data from a multicentre international study. Eur J Heart Fail 2019; 21: 1161–1164. https://doi.org/10.1002/ejhf.1565
- 15Estévez-Loureiro R, Shuvy M, Taramasso M, Benito-Gonzalez T, Denti P, Arzamendi D, et al. Use of MitraClip for mitral valve repair in patients with acute mitral regurgitation following acute myocardial infarction: Effect of cardiogenic shock on outcomes (IREMMI Registry). Catheter Cardiovasc Interv 2021; 97: 1259–1267. https://doi.org/10.1002/ccd.29552
- 16Haberman D, Estévez-Loureiro R, Czarnecki A, Melillo F, Adamo M, Villablanca P, et al. Transcatheter edge-to-edge repair in severe mitral regurgitation following acute myocardial infarction – aetiology-based analysis. Eur J Heart Fail 2025; 27: 912–921. https://doi.org/10.1002/ejhf.3582
- 17Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al.; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021; 385: 1451–1461. https://doi.org/10.1056/NEJMoa2107038
- 18Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al.; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383: 1413–1424. https://doi.org/10.1056/NEJMoa2022190
- 19Tromp J, Kosiborod MN, Angermann CE, Collins SP, Teerlink JR, Ponikowski P, et al. Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction – results from the EMPULSE trial. Eur J Heart Fail 2024; 26: 963–970. https://doi.org/10.1002/ejhf.3218
- 20Zhou W, Chen C, Chen Z, Liu L, Jiang J, Wu Z, et al. NLRP3: A novel mediator in cardiovascular disease. J Immunol Res 2018; 2018:5702103. https://doi.org/10.1155/2018/5702103
- 21Dyck JRB, Sossalla S, Hamdani N, Coronel R, Weber NC, Light PE, et al. Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects. J Mol Cell Cardiol 2022; 167: 17–31. https://doi.org/10.1016/j.yjmcc.2022.03.005
- 22Benedetti R, Chianese U, Papulino C, Scisciola L, Cortese M, Formisano P, et al. Unlocking the power of empagliflozin: Rescuing inflammation in hyperglycaemia-exposed human cardiomyocytes through comprehensive multi-level analysis. Eur J Heart Fail 2025; 27: 844–856. https://doi.org/10.1002/ejhf.3566
Citing Literature
